Advances in epigenetic therapeutics with focus on solid tumors

Clinical Epigenetics

James Herman¹  Kai He²  Ning Jin²  David Carbone²  Tiffany L. George²  Gregory A. Otterson²  Claire Verschraegen²  Erin M. Bertino²  Haitao Wen³ 

[1] Department of Medicine, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA;The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH, USA;The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH, USA;Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USA;

关键词: Epigenetic;    Therapeutics;    Therapies;    Cancer;    Methylation;    Acetylation;    Reprogramming;   

DOI  :  10.1186/s13148-021-01069-7

来源: Springer

【 摘 要 】

Epigenetic (“above genetics”) modifications can alter the gene expression without altering the DNA sequence. Aberrant epigenetic regulations in cancer include DNA methylation, histone methylation, histone acetylation, non-coding RNA, and mRNA methylation. Epigenetic-targeted agents have demonstrated clinical activities in hematological malignancies and therapeutic potential in solid tumors. In this review, we describe mechanisms of various epigenetic modifications, discuss the Food and Drug Administration-approved epigenetic agents, and focus on the current clinical investigations of novel epigenetic monotherapies and combination therapies in solid tumors.

【 授权许可】

CC BY